U.S. markets closed
  • S&P 500

    +8.26 (+0.19%)
  • Dow 30

    +13.36 (+0.04%)
  • Nasdaq

    +49.09 (+0.35%)
  • Russell 2000

    +24.40 (+1.06%)
  • Crude Oil

    +0.49 (+0.70%)
  • Gold

    -16.90 (-0.89%)
  • Silver

    +0.02 (+0.07%)

    -0.0071 (-0.58%)
  • 10-Yr Bond

    +0.0030 (+0.21%)

    -0.0060 (-0.42%)

    +0.2870 (+0.26%)

    -974.55 (-2.64%)
  • CMC Crypto 200

    -17.62 (-1.87%)
  • FTSE 100

    +45.88 (+0.65%)
  • Nikkei 225

    -9.83 (-0.03%)

4 Biotech Stocks Making Moves on Wednesday (2/6/19)

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

CORAL GABLES, FL / ACCESSWIRE / February 6, 2019 / In order for the biotech stock market to be successful, companies in the industry are tasked with not only maintaining a constant stream of innovative drug treatments as medical experts discover new diseases, but they must also meet the demands of consumers who have their own set of needs and expectations. According to a recent report from Deloitte regarding research and development for drug development, it costs nearly $2 billion to bring a new drug to market. In order to have this type of capital, companies in the biotech sector are constantly working to stay ahead of the ball by strategically investing in the development of products and services meant to improve the quality of life for consumers. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Pulmatrix Inc (PULM), MacroGenics Inc (MGNX), and Proteostasis Therapeutics Inc (PTI) represent four biotech companies creating nuanced approaches to further the advancement of modern medicine.

Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network. The Company has seen impressive gains over the last few months as a result of momentum gained from several key strategic investments which demonstrate Premier's dedication to the betterment of the biotech industry, and more importantly, to consumers looking to enhance their quality of life.

Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced at the tail-end of last month that, further to its news release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.

Per the official details of the agreement, Premier will pay to the Cloud Practice shareholders total consideration of up to $5 million, $2 million dollars in cash to be paid out as follows: (i) $500,000 paid in cash on signing of the binding LOI as a refundable deposit, (ii) $500,000 in cash payable on closing, (iii) $500,000 in cash payable 90 days after closing, (iv) $500,000 in cash payable within six months of the LOI subject to the satisfaction of certain milestones related to the integration of the Juno EMR, and $3 million payable in common shares of Premier at a deemed price of $0.76 per share.

Dr. Essam Hamza, CEO of Premier Health Group (OTC:PHGRF) (CSE:PHGI), commented, "we are very excited to have completed this acquisition and to have the experienced team at Cloud Practice join the team at Premier Health. With this acquisition, we now have a medical software company with national reach. Thus, enabling us to build on our patient-centric technology platform that will integrate telemedicine, online booking and other premium services with our electronic medical records (EMR) system."

For More Information On Premier Health Group, Click Here

Pulmatrix Inc (PULM) earlier this week announced a 1-for-10 reverse split of its common stock, effective as of 5:00 pm Eastern Time, February 5, 2019. Beginning on February 6, 2019, the Company's common stock will trade on the NASDAQ Capital Market on a split-adjusted basis.

Per the details of the announcement, the reverse stock split will cause a reduction in the number of shares of common stock outstanding and issuable upon the conversion of the Company's outstanding shares of preferred stock and the the exercise of its outstanding stock options and warrants in proportion to the ratio of the reverse stock split and will cause a proportionate increase in the conversion and exercise prices of such preferred stock, stock options and warrants.

For More Information On Pulmatrix Inc, Click Here

MacroGenics Inc (MGNX) saw impressive gains in the market on Wednesday, with shares soaring 133.45% just before noon, trading at $25.77 per share. The sudden increase may be connected to the Company's announcement today of positive results from SOPHIA, the Company's Phase 3 clinical study of margetuximab in HER2-positive metastatic breast cancer patients.

Per the official details of the Phase 3 results, Patients in the margetuximab arm experienced a 24% risk reduction in PFS compared to patients in the trastuzumab arm (HR=0.76, p=0.033). Notably, approximately 85% of patients in the study were carriers of the CD16A (FcγRIIIa) 158F allele, which has been previously associated with diminished clinical response to HERCEPTIN and other antibodies.

Scott Koenig, CEO, and President of MacroGenics, commented, "we are pleased with the SOPHIA clinical results and are especially grateful to the patients, their caregivers, trial investigators, and site personnel who participated in the study."

For More Information on MacroGenics Inc, Click Here

Proteostasis Therapeutics Inc (PTI), a clinical-stage biopharmaceutical company dedicated to treating cystic fibrosis, today announced that Emmanuel Dulac, PharmD, Ph.D., and Kim Cobleigh Drapkin, CPA, have been appointed to the Company's Board of Directors. Both the new appointees will hopefully bring their years of leadership experience to the Proteostasis team.

Following the announcement, Meenu Chhabra, President and CEO of Proteostasis, said, "collectively, Emmanuel's clinical development and commercial expertise, particularly in cystic fibrosis, and Kim's experience working for a broad range of growing biotech companies, will provide PTI valuable insight as we approach multiple key data readouts of our proprietary combinations and add-on CF therapies."

For More Information On Proteostasis Therapeutics Inc, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 (CASH) for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

Contact Information:


SOURCE: StockPrice.com

View source version on accesswire.com: